May Hyperthermia Conference Events

A friendly reminder that the main Hyperthermia conference events in the US, Europe and ASIA, (STM, ESHO, ACHO) are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.

The 35th Annual Meeting of the Society for Thermal Medicine, 32nd Annual Meeting of the European Society for Hyperthermic Oncology and 7th Annual Asia Conference of Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.

Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.

Who Should Attend?

• Researchers in the field of thermal oncology
• Clinicians, new to the field, who would like to talk with experts
• Clinicians who want to expand their thermal oncology program
• Medical Students that want to understand how hyperthermia may impact the future of medicine.
• Pyrexar Distributors who want to expand their working knowledge of hyperthermia
• Potential purchasers of hyperthermia equipment

Here are some dates to help you plan

Hope to see you there!

Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study

Phase III Soft Tissue Sarcoma + Chemotherapy

Authors: Issels RD1, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H, Peter K, Wilmanns W.
Publication: J Clin Oncol. 1990 Nov;8(11):1818-29.

PURPOSE:
From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide.

Read more ...